Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men

被引:37
|
作者
Dumond, Julie B. [1 ]
Reddy, Y. Sunila [1 ]
Troiani, Luigi [1 ]
Rodriguez, Jose E. [2 ,3 ]
Bridges, Arlene S. [1 ]
Fiscus, Susan A. [1 ]
Yuen, Geoffrey J. [4 ]
Cohen, Myron S. [1 ]
Kashuba, Angela D. M. [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ Puerto Rico, Sch Med, Dept Biochem, San Juan, PR 00936 USA
[3] Puerto Rico Inst Forens Sci, San Juan, PR USA
[4] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
HIV; pharmacokinetics; nucleoside triphosphate; antiretroviral therapy; genital tract;
D O I
10.1097/QAI.0b013e31816de21e
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To quantitate extracellular and intracellular zidovudine (ZDV) and lamivudine (3TC) concentrations in blood and semen of HIV-1-infected men. Design: Nonblind, single-center, open-label pharmacokinetic (PK) study in 14 subjects receiving ZDV plus 3TC. Methods: Paired blood and semen samples were obtained during I intensive visit and 3 single time point visits over 2 weeks. Extracellular ZDV and 3TC concentrations were measured in blood plasma (BP) and seminal plasma (SP), and intracellular ZDV and 3TC triphosphate (TP) concentrations were measured in isolated mononuclear cells using validated methods. HIV-1 RNA was measured in blood and semen. PK parameters were estimated using non-compartmental analysis. Results: Median (interquartile range [IQR]) SP/BP area under the time-concentration curve over the 12-hour dosing interval (AUC(0-12h)) ratios for ZDV and 3TC were 2.28 (1.48 to 2.97) and 6.67 (4.10 to 9.14), respectively, whereas individual SP/BP concentration ratios ranged from 1.9 to 91.4. Intracellular median (IQR) SP/BPAUC(0-12h) ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9. HIV-1 RNA was undetectable in both compartments. Conclusions: ZDV and 3TC SP exposures are 2- to 6-fold greater than BP exposures. Seminal ZDV-TP exposures are similar to 40% of those found in peripheral blood mononuclear cells (PBMCs), whereas 3TC-TP exposures are similar to PBMC exposures. PK variability makes individual SP/BP ratios a suboptimal surrogate for genital tract exposure.
引用
收藏
页码:156 / 162
页数:7
相关论文
共 50 条
  • [1] Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men
    Taylor, S
    van Heeswijk, RPG
    Hoetelmans, RMW
    Workman, J
    Drake, SM
    White, DJ
    Pillay, D
    [J]. AIDS, 2000, 14 (13) : 1979 - 1984
  • [2] Elvitegravir concentrations in seminal plasma in HIV-1-infected men
    Imaz, A.
    Niubo, J.
    Kashuba, A. D.
    Ferrer, E.
    Sykes, C.
    Rozas, N.
    Acerete, L.
    Vila, A.
    Podzamczer, D.
    [J]. HIV MEDICINE, 2017, 18 (03) : 225 - 230
  • [3] Penetration of didanosine in semen of HIV-1-infected men
    Cruciani, M
    Liuzzi, G
    Chirianni, A
    Audagnotto, S
    Bonora, S
    Biagio, A
    Sinicco, A
    Bassetti, M
    Gatti, G
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (06) : 1244 - 1247
  • [4] Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults
    Goodgame, JC
    Pottage, JC
    Jablonowski, H
    Hardy, WD
    Stein, A
    Fischl, M
    Morrow, P
    Feinberg, J
    Brothers, CH
    Vafidis, I
    Nacci, P
    Yeo, J
    Pedneault, L
    [J]. ANTIVIRAL THERAPY, 2000, 5 (03) : 215 - 225
  • [5] Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
    Kuritzkes, DR
    Shugarts, D
    Bakhtiari, M
    Poticha, D
    Johnson, J
    Rubin, M
    Gingeras, TR
    Kennedy, M
    Eron, JJ
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (01): : 26 - 34
  • [6] Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
    Zhou, XJ
    Havlir, DV
    Richman, DD
    Acosta, EP
    Hirsch, M
    Collier, AC
    Tebas, P
    Sommadossi, JP
    [J]. AIDS, 2000, 14 (18) : 2869 - 2876
  • [7] Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults:: a randomized trial
    Matheron, S
    Descamps, D
    Boué, F
    Livrozet, JM
    Lafeuillade, A
    Aquilina, C
    Troisvallets, D
    Goetschel, A
    Brun-Vezinet, F
    Mamet, JP
    Thiaux, C
    [J]. ANTIVIRAL THERAPY, 2003, 8 (02) : 163 - 171
  • [8] Antiretroviral drug concentrations in semen of HIV-1 infected men
    Taylor, S
    Pereira, AS
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2001, 77 (01) : 4 - 11
  • [9] Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men
    Taylor, S
    Reynolds, H
    Sabin, CA
    Drake, SM
    White, DJ
    Back, DJ
    Pillay, D
    [J]. AIDS, 2001, 15 (15) : 2051 - 2053
  • [10] Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
    Staszewski, S
    Miller, V
    Rehmet, S
    Stark, T
    DeCree, J
    DeBrabander, M
    Peeters, M
    Andries, K
    Moeremans, M
    DeRaeymaeker, M
    Pearce, G
    VanDenBoeck, R
    Verbiest, W
    Stoffels, P
    [J]. AIDS, 1996, 10 (05) : F1 - F7